🚨Moon Central Mag🚨

Finding Liquidity in stocks, Crypto, Meme Coins, Futures, Etc.

[🚨Moon Central Mag🚨 @MCmagnificent]

Modifier gene therapy from Ocugen is wild: one shot of NR2E3 resets entire retinal gene networks, restoring homeostasis across 100+ RP mutations. It doesn’t fix one gene—it makes cells resilient to any mutation. 100% showed benefit in Phase 1/2. Root-cause attack on blindness. $OCGN 🚀

[🚨Moon Central Mag🚨 @MCmagnificent]

$Hims & Hers dropped a savage Super Bowl ad: "Rich people live longer" calling out the health-wealth gap & declaring healthcare ain't a luxury anymore. Then BAM—$1.15B acquisition of Eucalyptus to go global (Australia, UK, Germany, Japan, Canada incoming). Weight-loss drama? They're still scaling HARD. 💥 #HIMS #HealthEquity

[🚨Moon Central Mag🚨 @MCmagnificent]

Ocugen to release Q4/full-year 2025 financials & business update on March 4, 2026, with 8:30 AM ET call. Positive OCU410 Phase 2 results (~46% lesion reduction in GA/dAMD, clean safety) + advancing OCU400 Phase 3 fuel momentum in gene therapies for blindness.👁️ $OCGN #GeneTherapy

[🚨Moon Central Mag🚨 @MCmagnificent]

@Chef_Enrico $1.59 swept highs to grab liquidity + trap breakout chasers, then flushed straight back to $1.54 to shaking weak hands. Classic stop-hunt + fakeout. They clear the shelf before the real move. Wait for confirmation or next sweep. Don’t chase the noise.🚀📉📈📉 $OCGN has potential!

[🚨Moon Central Mag🚨 @MCmagnificent]

$OCGN is a high-risk/high-reward speculative play. 2026 is pivotal: key data readouts, potential BLA filings & March 4 earnings call. Big upside if the modifier gene therapy platform transforms inherited blindness treatment—but steep downside if trials miss or funding tightens.

[🚨Moon Central Mag🚨 @MCmagnificent]

@Chef_Enrico Hopefully prophetic timing. 😃

[🚨Moon Central Mag🚨 @MCmagnificent]

Trading Essentials 📚 🔍🕵🏽

[🚨Moon Central Mag🚨 @MCmagnificent]

Hims & Hers quietly building one of the most convenient ways to get real medical help: quick consults, custom treatments, pharmacy shipped fast. Destigmatizing wellness one category at a time. #DigitalHealth #Hims $HIMS ❤️

[🚨Moon Central Mag🚨 @MCmagnificent]

Stargardt disease has no approved treatments yet. OCU410ST from Ocugen could be the first disease-modifying option. Watching the data closely. #RareDisease #OCGN Ocugens on the case.

[🚨Moon Central Mag🚨 @MCmagnificent]

@Sports_JournalX For sure. 😎

[🚨Moon Central Mag🚨 @MCmagnificent]

$OCGN insiders know OCU410 is the real dry AMD game-changer, but Big Pharma will try to bury it like they do EVERY threat. 46-57% lesion reduction? That's not 'promising'—that's a threat to billion-dollar eye drops. Shorts are cooked. 🩸🚀 #Ocugen

[🚨Moon Central Mag🚨 @MCmagnificent]

Tesla's dumping $20B+ into robotaxis and Optimus while killing off the Model S/X as EV sales tank. Musk pivots from cars to sci-fi bets while China crushes them. Legacy holders bailing—cult stock or dying EV king? Shorts loading up. 🔥📉 #TSLA. Who’s holding? $TSLA

[🚨Moon Central Mag🚨 @MCmagnificent]

Ocugen ($OCGN) continues to prioritize its gene therapy programs targeting blindness-related conditions, building fresh momentum from recent clinical advancements and key corporate developments.

[🚨Moon Central Mag🚨 @MCmagnificent]

$GALT ’s dilution confusion is killing retail: FDA feedback tanks it 30%, shorts pile on, yet they quietly extend runway with $10M credit line. Belapectin breakthrough or endless share printer? Shkreli laughs while longs cry. Pump, dump, repeat?📉🩸Don’t get caught in the wave.🌊